The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.
A61K 31/737 - Polysaccharides sulfatés, p. ex. sulfate de chondroïtine, sulfate de dermatane
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE).
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE).
The present invention is directed to the use of the heparin derivative tafoxiparin in the treatment of preeclampsia (PE). The treatment may be monotherapy or combination therapy, where tafoxiparin is used in combination with an agent (drug) used as standard of care therapy in preeclampsia (PE).
A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
7.
Processes for the production of chemically-modified heparins
The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.
The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 lU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 lU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
The present invention refers to the use of certain sulfated glycosaminoglycans for treatment of labor arrest. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with an agent capable of promoting myometrial contractions of the uterus and thereby re-establish effective labor.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
14.
COMBINATION TREATMENT COMPRISING SULPHATED GLYCOSAMINOGLYCANS FOR INDUCING LABOR
The present invention refers to the use of certain sulfated glycosaminoglycans for inducing labor. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are used in a combination therapy together with treatment capable of promoting cervical ripening or capable of promoting myometrial contractions of the uterus.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
15.
NON ANTI-COAGULATIVE GLYCOSAMINOGLYCANS COMPRISING REPEATING DISACCHARIDE UNIT AND THEIR MEDICAL USE
The present invention relates to a chemically modified glycosaminoglycanwith an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average)fromabout 4.6 to6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycanand its medical uses.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
The present invention relates to chemically modified sulfated glycosaminoglycan derivatives selected from the group of heparin, heparan sulfate, dermatan sulfate and chondroitin sulphate with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the derivatives and their medical uses, including treatment of malaria and treatment of vaso-occlusive crisis in sickle cell disease.
The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
The present invention relates to a chemically modified glycosaminoglycanwith an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average)fromabout 4.6 to6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycanand its medical uses.
A61P 15/04 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour le déclenchement de l'accouchement ou de l'avortementUtérotoniques
20.
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
21.
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
brevets
